Advanced Filters
noise

Winchester, Massachusetts Clinical Trials

A listing of Winchester, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,782 clinical trials
N Nadine J. McCleary, MD, MPH

Resilience and Equity in Aging, Cancer, and Health (REACH)

The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

70 years of age All Phase N/A
J Jorge J. Castillo, MD

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) Venetoclax (a BCL2 inhibitor)

18 years of age All Phase 2
G Guang-Shing Cheng, MD

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: …

18 years of age All Phase 2

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to …

18 - 55 years of age All Phase N/A
G Gabriela Hobbs, MD

Ruxolitinib in Thrombocythemia and Polycythemia Vera

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). This research study involves the study drug Ruxolitinib.

18 years of age All Phase 2
S Stacey Ellender, PhD

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

21 years of age All Phase 2

Mind Body Syndrome Therapy for Chronic Pain

The goal of this study is to determine if a mind-body intervention can help people suffering from chronic back pain. The study is a randomized, partially blinded trial examining the effectiveness of a mind body intervention in reducing disability from back pain and alleviating back pain in participants as compared …

18 - 67 years of age All Phase N/A
J Jamie Micco, PhD

Digital Single Session Intervention for Youth Mental Health

The aim of this study is to test the effectiveness of a single-session, digital intervention teaching the principle of practicing the opposite, when administered to youths on the waitlist for psychotherapy, with usual waitlist procedures as a control condition.

9 - 17 years of age All Phase N/A
M Michael Osborne, MD

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

This study aims to evaluate the effect of 8 weeks of a stress reduction intervention on atherosclerotic plaque inflammation in adults with stable coronary artery disease, as quantified by positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in individuals with increased psychosocial stress.

45 - 65 years of age All Phase N/A
N Nicole Calianese

Pharmacological Activation of HMN for OSA Aim 2

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators …

18 - 70 years of age All Phase 1/2

Simplify language using AI